Posts Tagged ‘Master in Biotechnology Management#8217;

January 16, 2012

New Appointments from our Alumni: Alejandro Portilla

Written on January 16, 2012 by blended.team in Careers, Life Sciences, News

Alejandro PortillaWe are pleased to announce that one of our Master in Biotechnology Management alumni (2009-10 intake), Alejandro Portilla has been named Established Products, EMEA West and East Commercial Manager, S&OP and NPI.

Previously, Alejandro was the Business Excellence Manager for Europe and Canada in GPO.

Alejandro began his career in Abbott 14 years ago as the Abbott International Head of Customer Service in Guatemala. During his tenure he has also been a Logistics Coordinator for Latin America, a Senior Export Planner, as well as a Demand Manager for Latin America and Canada. Prior to joining Abbott, Alejandro worked in multiple supply chain roles in Tata and Colgate Palmolive. Alejandro holds a Bachelors degree in Industrial Engineering from Universidad Rafael Landivar in Guatemala, and a Master in Biotechnology Management from Instituto de Empresa Business School in Spain.

Please join us in congratulating Alejandro on his new role.

November 17, 2011

Honors and awards for our MBM Alumni: Jesús Gómez

Written on November 17, 2011 by blended.team in Entrepreneurship, MBM News

Jesús Gómez Ochoa de Alda

Jesús Gómez Ochoa de Alda

From the Master in Biotechnology Management team, we are extremely proud to announce that another of our brilliant Alumni has been distinguished with the first prize at the Campus Emprende 2011 Business Plan Competition 

This Entrepreneurship-renowned Competition  has awarded  Jesus Gómez Ochoa de Alda (MBM 2011) with €10,000 in cash for his Biotech plan: a project to develop and market a microalgae harvesting system.

The lack of economically viable harvesting processes remains a major obstacle to commercial biofuel production from microalgae.

After this successful milestone in his career as an entrepreneur, Jesús Gómez will launch an spin-off, Green Biodrift, to develop the system using comparative genomics and synthetic biology.

October 24, 2011

MBM Students Talk!

Written on October 24, 2011 by blended.team in Careers, MBM News

The first Face- to- Face period in Madrid is over!

Our Master in Biotechnology Management students are back home with a bunch of academic and personal experiences but with a long way ahead…

Check out what they have to say and stay tuned to our MBM Playlist!

MBM Playlist

October 17, 2011

The new MBM intake is here!

Written on October 17, 2011 by blended.team in Careers, MBM News

The Master in Biotechnology Management 2011 intake is here in Madrid in the first face-to-face period.

We are capturing their first insights about the program, as well as the essence of the Master through interviews and pictures.

Click the image below and stay tuned to the MBM´s playlist, as we will be adding more material along the following weeks.

IEstethoscope

October 6, 2011

Our Alumni are changing the World!

Written on October 6, 2011 by blended.team in Life Sciences, MBM News, Medicine & Healthcare

The 2011 MIT TR35 winners are already shaping the future,  and in this edition Teresa Gonzalo and Damiá Tormo (MBMAlumni) have been honored with this award.

   Teresa Gonzalo            Damiá Tormo                  

Each year the Massachusetts Institute of Technology (MIT) honors 35 innovators under 35 who are tackling important problems in transformative ways. Candidates come from around the globe, some from regional TR35 competitions run by TR’s international editions.

CONGRATULATIONS”

September 15, 2011

Filling the gap between the Academia and the Markets

Written on September 15, 2011 by blended.team in News

Rafael Camacho, CEO at Genoma España, shares his view about the need to fill the gap between the Academia and the Markets in the Biotech industry.
Entrepreneuring in Biotech sector is tough but there are many tools to start a business…

September 13, 2011

From Disney to Direct Sales

Written on September 13, 2011 by blended.team in News

What do Disney and Herbalife have in common and why is direct selling the original social networking business model?

Click the image below and follow the presentation LIVE from your home or school…

September 1, 2011

Professor Greuel at the EPMA World Congress 2011

Written on September 1, 2011 by blended.team in News

Dr. Joachim Greuel Our Academic Director and Professor of Finance & Healthcare Management  Dr. Joachim Greuel,  will attend as one of the most renowed speakers at the EPMA World Congress 2011 in Bonn as part of the team of the specialised session “National and International Granting Strategies in PPPM: Innovative Programmes, Economy of Personalised Medicine”.

 

 The Congress will take place the 16th Sept 2011 at the Parliament of Federal Republic of Germany (Bundeshaus)

Parliament of Federal Republic of Germany

August 6, 2011

Reviews from the Industry by Joachim Greuel

Written on August 6, 2011 by blended.team in MBM News, News, Pharma Industry

Reviews from the Industry: Today, our academic director Joachim Greuel sets the focus on Biotech Stocks and the relevance of pricing decisions in the Companies.

 Biotech Stocks Vulnerable to Economic Concerns 

Biotech Stocks

 Last Thursday, 4 August 2011 the NASDAQ Biotechnology and the AMEX Biotechnology indices lost 8% and 11%, respectively, while the AMEX Pharmaceutical index fell only 4%. The last time a similar downturn was observed was in 2008.

This demonstrates, once more, that biotech stocks with highly volatile cash flows are more vulnerable to the general economic environment than stocks of more established firms.

While this may not come as a surprise, some biotech companies suffer more from general market conditions than others.

As a consequence, management should design strategies to minimize volatility as much as possible, also in order to reduce its cost of capital.

 In our MBM courses we will discuss strategies how this may be accomplished.

Dendreon Falls 67% After Lower Than Expected Provenge Sales

Dendreon Case

 Last  Thursday, 4 August 2011, Dendreon stock fell 67% (by $24.15 to $11.69) after the company reported a lower than expected uptake of its recently (April 2010) approved cancer cell therapy Provenge.

As Provenge is the first available autologous cellular immunotherapy against cancer worldwide, the stock has received significant attention. It is believed that the therapy’s high price prevents a rapid market penetration. Although the US federal agency CMS has determined that Medicare will reimburse the therapy that costs over $90,000.-, the therapy’s cost-effectiveness has been questioned as it extends life by no more than four months, on average.

The Dendreon case demonstrates the importance of  pricing decisions: innovative therapies that do not demonstrate a clear cost-effectiveness will penetrate the market much slower than they would with a shown, undisputable pharmacoeconomic benefit. Thus, pricing decisions are no longer solely driven by market studies such as conjoint analyses, but also by outcomes research. Biotech managers that often tend to focus on R&D should think about pharmacoeconomics; the likelihood of a good licensing deal, for example, also depends on pharmacoeconomic aspects 

July 12, 2011

Success Story!

Written on July 12, 2011 by blended.team in Careers, MBM News, Pharma Industry

Our alumni ATSUSHI SHIMADA  of the Master in Biotechnology Management  2010

shares his successful career upgrade at TAKEDA Pharmaceuticals… 

Hi everybody!ATSUSHI SHIMADA

Mi name is Atsushi Shimada and now I can proudly say that I am the Business Development Manager in Singapore for TAKEDA Pharmaceuticals.

Actually, after the master, I was not only earlier promoted to the manager’s position but also elected to a global career development program which could prepare me for a potential senior or top management position.  At this program, I will have a two-year residence period in any one of our companies’ subsidiaries in the world where I am going to experience business development, marketing, finance, business intelligence, etc. 

This was possible after requesting our company to send me to the representative successful biotech company, about which we had a class in the strategy course.  I was so lucky since only two persons among 10,000 employees in our company can be nominated to this program per year and I am one of the two!!  I think all these luck comes from my study at IE Master in Biotechnology Management!!! 

I very much appreciate it.

We use both our own and third-party cookies to enhance our services and to offer you the content that most suits your preferences by analysing your browsing habits. Your continued use of the site means that you accept these cookies. You may change your settings and obtain more information here. Accept